Search the Newsreel

Colombier Acquisition Corp. III (CLBR) earns $2.8M on $302M SPAC trust in H1 2026

Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend

Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Colombier Acquisition Corp. III Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029

Aktis Oncology reported its Q2 2026 results, highlighting progress in its targeted radiopharmaceutical pipeline with promising early data for AKY-2519 and ongoing trials for AKY-1189. The company maintains a strong financial position with $517.3 million in cash, cash equivalents, and marketable securities, projected to …

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Aktis Oncology reported its financial results and business highlights for the second quarter of 2026, showcasing strong execution and progress in its clinical pipeline. The company presented promising first-in-human clinical imaging and dosimetry data for AKY-2519 and is actively enrolling patients in Phase 1b …

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

Analysts have provided insights on two healthcare companies: Neurogene (NGNE) and Cardiff Oncology (CRDF). Neurogene received a "Strong Buy" consensus with a significant upside, while Cardiff Oncology received a "Moderate Buy" consensus despite a recent downgrade to "Hold" by one analyst.

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The study showed a statistically significant …

Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside

Analysts have raised the average 12-month price target for Kura Oncology, Inc. (KURA) stock from $31.17 to $32, with forecasts ranging from $15 to $76 per share. This new target suggests a potential upside of approximately 222% from its August 12 closing price. The …

Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings

CG Oncology (CGON) Faces A Fair Value Gap Following Its Latest Earnings

CG Oncology recently reported its Q2 and H1 2026 earnings, showing revenue of US$1.16 million for the quarter and a net loss of US$79.06 million. Despite being a loss-making company, a discounted cash flow (DCF) model by Simply Wall St estimates a fair value …

Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush

Wedbush has increased its price target for Kura Oncology (NASDAQ:KURA) to $38.00 from $36.00, maintaining an "outperform" rating, which suggests a significant upside of 282.29% from its current stock price. This comes after Kura Oncology reported better-than-expected quarterly results, with a narrower loss per …

Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Pyxis Oncology, Inc. announced its financial results for the second quarter and six months ended June 30, 2026. For the second quarter, the company reported a net loss of $25.35 million, an increase from $18.35 million in the prior year, with a basic and …

Pyxis Oncology Q2 loss widens 38%, misses EPS estimate

Pyxis Oncology reported a Q2 2026 net loss of $25.3 million, or ($0.40) per share, which widened by 38% year-over-year and missed analyst estimates due to a significant increase in general and administrative expenses. The company secured $50 million in new financing, extending its …

Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary

Pyxis Oncology, Inc. reported its Q2 2026 financial results, showing $0 in revenue and a net loss of $25.35M, leading to a diluted EPS of $(0.40). This compares to Q2 2025 revenue of $2.82M and a net loss of $18.35M. The company highlighted continued …

Form 8K Pyxis Oncology Inc For: 13 August By Investing.com

This article announces that Pyxis Oncology Inc. has filed a Form 8K on August 13. The brief piece provides no further details beyond the filing announcement. It includes stock market data and other Investing.com features.

Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating

Wedbush has increased its price target for Kura Oncology (KURA) shares to $38 from $36, while maintaining an Outperform rating on the stock. This adjustment comes as the company continues its clinical development in precision medicine for cancer treatment. Kura Oncology is focused on …

Pyxis Oncology expects two MICVO cancer-study data updates in 2026

Pyxis Oncology reported a Q2 2026 net loss of $25.3 million but strengthened its financial position with a private placement of up to $114 million, extending its cash runway into Q2 2027. The company anticipates key clinical data readouts for its lead candidate, MICVO, …

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology (Nasdaq: PYXS) reported its second-quarter 2026 financial results, highlighting progress in its MICVO clinical development programs and an extended cash runway into Q2 2027 following a $114 million private placement. The company is set to release updated data from the MICVO Phase …

Why is Cullinan Oncology stock surging today? By Investing.com

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology, a biopharmaceutical company, announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent director to its Board, expanding it to nine members. Dr. Peri brings extensive leadership experience in higher education, financial services, law, and corporate governance, which is expected to …

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for zipalertinib combined with chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung …

Cullinan, Taiho's Zipalertinib - Chemotherapy Combo Meets Key Goal In Phase 3 NSCLC Trial; Stock Up

(RTTNews) - Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (CGEM) announced that the Phase 3 REZILIENT3 trial, evaluating the combination of zipalertinib and platinum-based chemotherapy in the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), met …

Earnings call transcript: Kura Oncology tops Q2 2026 estimates as launch gains

Kura Oncology reported strong Q2 2026 results, exceeding Wall Street expectations due to robust early sales of its new cancer drug KOMZIFTI. The company posted a smaller-than-expected loss and higher revenue, driven by KOMZIFTI capturing a majority share of new patient starts in the …

Kura Oncology (NASDAQ:KURA) Issues Earnings Results

CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise

An insider at CG Oncology, Ambaw Bellete, has filed to sell 32,137 common shares of CGON through Morgan Stanley Smith Barney LLC. This proposed sale is linked to a stock option exercise on August 12, 2026, with an aggregate market value of over $2.5 …

Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates

Kura Oncology (KURA) reported a Q2 loss of $0.77 per share, beating the Zacks Consensus Estimate of a $0.89 loss, and revenues of $20.87 million, surpassing estimates by 23.61%. Despite underperforming the S&P 500 year-to-date, the stock holds a Zacks Rank #2 (Buy) due …

Kura Oncology Reports Second Quarter 2026 Financial Results

Kura Oncology announced its second quarter 2026 financial results, highlighting strong commercial performance for its drug KOMZIFTI® (ziftomenib), which generated $9.1 million in net product revenue and achieved a majority share of new patient starts in its class. The company also provided updates on …

Kura Oncology: Q2 Earnings Snapshot

Kura Oncology (KURA) grows revenue to $39.1M but widens net loss

Earnings Flash (KURA) Kura Oncology, Inc. Reports Q2 Revenue $20.9M, vs. FactSet Est of $20.2M

Kura Oncology, Inc. (KURA) reported Q2 revenue of $20.9 million, surpassing FactSet's estimated $20.2 million. This earnings flash indicates a positive revenue surprise for the biotechnology and medical research company. The report also mentions other recent financial news, including a widened Q2 diluted loss …

Cardiff Loss Narrows In Q2; Directs Resources To Phase 3 For Onvansertib In Q1 '27

(RTTNews) - Cardiff Oncology, Inc. (CRDF) a clinical-stage oncology company, reported second quarter results, reflecting a narrower loss primarily driven by lower operating expenses. The company in particular noted reduced Research and Development (R&D) expenses following the completion of clinical trials and lesser preclinical …

Form 8K Citius Oncology Inc For: 12 August By Investing.com

This article announces the filing of a Form 8K by Citius Oncology Inc. on August 12, 2026. The content is brief and primarily serves as a news alert for the filing, with a focus on market data and other news. Citius Oncology Inc. (CTOR) …

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com

Citius Oncology, Inc. has appointed Jonathan Peri, Ph.D., J.D., as an independent director to its board, expanding it to nine members. Peri brings 30 years of experience in higher education, financial services, law, and corporate governance. The company, a subsidiary of Citius Pharmaceuticals, Inc., …

New Citius Oncology director brings college, legal and bank experience

William Blair Downgrades Cardiff Oncology to Market Perform From Outperform

William Blair has downgraded Cardiff Oncology (CRDF) from an "Outperform" rating to "Market Perform." This comes shortly after Cardiff Oncology reported its earnings results for the second quarter and six months ended June 30, 2026. The company is a clinical-stage biotechnology firm focused on …